Highlights of the latest treatments.
At this year's meeting of the American Society of Clinical Oncology (ASCO 2021), held virtually June 4–8, investigators discussed the latest findings in cancer research. Here, Editor-in-Chief William J. Gradishar, MD, reviews the key presentations on new breast cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.
Adjuvant Olaparib Reduces Recurrence in BRCA-Mutated Breast Cancer
Adjuvant olaparib, a poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, lowers recurrence risk in patients with germline BRCA-mutation–associated early breast cancer, according to results from a prespecified interim analysis of the OlympiA study presented at ASCO (abstract LBA1) and published in the New England Journal of Med…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)